Litcius/Paper detail

Second dose of the BNT162b2 mRNA vaccine: Value of timely administration but questionable necessity among the seropositive

Κωνσταντίνα Κοντοπούλου, Alexandra Ainatzoglou, Christos T. Nakas, Athina Ifantidou, Georgia Goudi, Eleni Antoniadou, Vasilios Adamopoulos, Nikitas Papadopoulos, Georgios Papazisis

2021Vaccine14 citationsDOIOpen Access PDF

Topics & Concepts

ImmunogenicityTiterMedicineCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VirologyPharmacologyImmunologyAntibodyInternal medicineDiseaseInfectious disease (medical specialty)SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesCOVID-19 epidemiological studies
Second dose of the BNT162b2 mRNA vaccine: Value of timely administration but questionable necessity among the seropositive | Litcius